𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The course of fever following influenza virus infection in children treated with oseltamivir

✍ Scribed by Eitaro Suzuki; Kiyoshi Ichihara


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
351 KB
Volume
80
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Although the effectiveness of oseltamivir against influenza virus infection is well known, there has been no report analyzing the detailed time course of fever following the drug treatment in children. Oseltamivir was prescribed for 4 days to every child with a positive result for rapid immunological test for influenza virus during 2002–2003, 2003–2004, and 2004–2005 epidemics. Only those who were 1–12 years of age and prescribed oseltamivir within 24 hr after the onset of fever were included in the analysis. The numbers of children with type A/H3N2 disease for the three seasons were 64, 77, and 33, and those with type B disease were 102, 4, and 86, for the respective seasons. The period until normalization of temperature was obtained from six‐hourly recordings of body temperature. By multiple regression analysis, temperature periods were longer in type B than in type A/H3N2 disease, negatively associated with age, and positively with maximal body temperature (all: P < 0.001). The effectiveness of oseltamivir on body temperature in type B disease was less apparent in the 2004–2005 than in the 2002–2003 season, irrespective of age. No such between‐season difference was observed for Type A/H3N2 disease. Frequencies of ineffective cases with biphasic fever (19.6% and 43.0% during 2002–2003 and 2004–2005 seasons) were significantly higher in type B than in type A/H3N disease (12.0% and 11.8%, respectively). The effectiveness of oseltamivir depends on a child's age, maximal body temperature and the virus type. This study confirmed recent reports indicating decreased effectiveness of oseltamivir against type B disease. J. Med. Virol. 80:1065–1071, 2008. © 2008 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Cascade of fever production in mice infe
✍ Kurokawa, Masahiko; Imakita, Masami; Kumeda, Cristina A.; Shiraki, Kimiyasu 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 666 KB

The cascade of fever production in influenza was studied. To analyse fever production in a murine model, we selected DBN2 mice that have the highest susceptibility in fibrile responses among seven mouse strains. lntranasal influenza infection-and interferon (IFN)-induced fever production was studied

Changes of serum hepatitis B virus DNA a
✍ Ping-Ing Lee; Mei-Hwei Chang; Chin-Yun Lee; Hong-Yuan Hsu; Juei-San Chen; Pei-Je 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 462 KB 👁 2 views

## DING-SHINN CHEN" During a follow-up period of 3.2 \* 1.6 (1 to 8.6) yr, 1,087 serum specimens from 230 HBsAg carrier children were tested for hepatitis B virus markers.

Parvovirus B19 quiescence during the cou
✍ Goedert, James J.; Erdman, Dean D.; Konkle, Barbara A.; Török, Thomas J.; Lederm 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 28 KB 👁 2 views

To detect and characterize parvovirus B19 infection during the course of progressive immune deficiency from human immunodeficiency virus (HIV), ten subjects enrolled in the Multicenter Hemophilia Cohort Study were followed for 6.4 to 15 years from HIV seroconversion through extreme immune deficiency

Seroprevalence of hepatitis B, hepatitis
✍ Kebudi, Rejin; Ayan, Inci; Y�lmaz, G�lden; Ak�c�, Ferhan; G�rg�n, �mer; Badur, S 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background. Children with cancer receiving intensive chemotherapy require multiple transfusions and are at increased risk for blood transmittable diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infections. Procedure. Sera from 50 children

Experimental approach to the study of im
✍ S. Cunningham-Rundles; R. Yeger-Arbitman; P. Edelson; D. Sanders; P. V. Giardina 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 647 KB

## Abstract The clinical immunology laboratory is often called on to assess risk in pediatric patients with clinical evidence of immunodeficiency and possible human immunodeficiency virus (HIV) exposure while antibody tests are being considered or are underway. Since non–HIV‐related conditions incl